Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Editorial Board Members’ Collection Series: "Cancer Biology and Therapeutics"
share announcement

Editorial Board Members’ Collection Series: "Cancer Biology and Therapeutics"

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 8033

Special Issue Editors

Prof. Dr. Antonio Biondi

grade E-Mail Website
Guest Editor
Department of General Surgery and Surgical—Medical Specialties, University of Catania, Catania, Italy
Interests: colorectal cancer; general surgery; screening; biomarkers; quality of life; liquid biopsy; microbiota
Special Issues, Collections and Topics in MDPI journals
Dr. Yun-Hee Kim

E-Mail Website
Guest Editor
Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang 10408, Republic of Korea
Interests: pancreatic cancer; cholangiocarcinoma; organoid; tumor microenvironment
Dr. Michele Ammendola

E-Mail Website
Guest Editor
Department of Health Science, Digestive Surgery Unit, Medical School, University “Magna Graecia”, Viale Europa, Germaneto, 88100 Catanzaro, Italy
Interests: surgical oncology; angiogenesis and lymphangiogenesis in gastrointestinal tumor; molecular aspects; traslational reserch in surgery
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Ciro Isidoro

E-Mail Website
Guest Editor
Laboratory of Molecular Pathology, Department of Health Sciences, Università del Piemonte Orientale “A. Avogadro”, Via Solaroli 17, 28100 Novara, Italy
Interests: autophagy and protein metabolism in cancer and in neurodegeneration; epigenetics in cancer; nutraceuticals and probiotics in cancer and infectious diseases
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Luciano Mutti

E-Mail Website
Guest Editor
Department of Biology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA
Interests: translational vancer research; thoracic oncology; mesothelioma
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to announce this collection entitled Editorial Board Members’ Collection Series: "Cancer Biology and Therapeutics". This issue will be a collection of papers by researchers invited by the Editorial Board Members. The aim is to provide a venue for networking and communication between Biomedicines and scholars in the field of cancer biology and therapeutics. All papers will be fully open access upon publication after peer review.

Prof. Dr. Antonio Biondi
Dr. Yun-Hee Kim
Dr. Michele Ammendola
Prof. Dr. Ciro Isidoro
Prof. Dr. Luciano Mutti
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

25 pages, 8932 KiB  
Article
An Analysis of JADE2 in Non-Small Cell Lung Cancer (NSCLC)
by Ciara Murphy, Glòria Gornés Pons, Anna Keogh, Lisa Ryan, Lorraine McCarra, Chris Maria Jose, Shagun Kesar, Siobhan Nicholson, Gerard J. Fitzmaurice, Ronan Ryan, Vincent Young, Sinead Cuffe, Stephen P. Finn and Steven G. Gray
Biomedicines 2023, 11(9), 2576; https://doi.org/10.3390/biomedicines11092576 - 19 Sep 2023
Cited by 2 | Viewed by 2335
Abstract
The JADE family comprises three members encoded by individual genes and roles for these proteins have been identified in chromatin remodeling, cell cycle progression, cell regeneration and the DNA damage response. JADE family members, and in particular JADE2 have not been studied in [...] Read more.
The JADE family comprises three members encoded by individual genes and roles for these proteins have been identified in chromatin remodeling, cell cycle progression, cell regeneration and the DNA damage response. JADE family members, and in particular JADE2 have not been studied in any great detail in cancer. Using a series of standard biological and bioinformatics approaches we investigated JADE2 expression in surgically resected non-small cell lung cancer (NSCLC) for both mRNA and protein to examine for correlations between JADE2 expression and overall survival. Additional correlations were identified using bioinformatic analyses on multiple online datasets. Our analysis demonstrates that JADE2 expression is significantly altered in NSCLC. High expression of JADE2 is associated with a better 5-year overall survival. Links between JADE2 mRNA expression and a number of mutated genes were identified, and associations between JADE2 expression and tumor mutational burden and immune cell infiltration were explored. Potential new drugs that can target JADE2 were identified. The results of this biomarker-driven study suggest that JADE2 may have potential clinical utility in the diagnosis, prognosis and stratification of patients into various therapeutically targetable options. Full article
(This article belongs to the Special Issue Editorial Board Members’ Collection Series: "Cancer Biology and Therapeutics")
►▼ Show Figures

Figure 1

12 pages, 1296 KiB  
Article
CDC25C Protein Expression Correlates with Tumor Differentiation and Clinical Outcomes in Lung Adenocarcinoma
by Esther Stern, Guy Pines, Li Or Lazar, Gilad W. Vainer, Nitzan Beltran, Omri Dodi, Lika Gamaev, Ofir Hikri Simon, Michal Abraham, Hanna Wald, Amnon Peled and Ori Wald
Biomedicines 2023, 11(2), 362; https://doi.org/10.3390/biomedicines11020362 - 26 Jan 2023
Cited by 5 | Viewed by 1723
Abstract
Given that, even after multimodal therapy, early-stage lung cancer (LC) often recurs, novel prognostic markers to help guide therapy are highly desired. The mRNA levels of cell division cycle 25C (CDC25C), a phosphatase that regulates G2/M cell cycle transition in malignant cells, correlate [...] Read more.
Given that, even after multimodal therapy, early-stage lung cancer (LC) often recurs, novel prognostic markers to help guide therapy are highly desired. The mRNA levels of cell division cycle 25C (CDC25C), a phosphatase that regulates G2/M cell cycle transition in malignant cells, correlate with poor clinical outcomes in lung adenocarcinoma (LUAD). However, whether CDC25C protein detected by immunohistochemistry can serve as a prognostic marker in LUAD is yet unknown. We stained an LC tissue array and a cohort of 61 LUAD tissue sections for CDC25C and searched for correlations between CDC25C staining score and the pathological characteristics of the tumors and the patients’ clinical outcomes. Clinical data were retrieved from our prospectively maintained departmental database. We found that high expression of CDC25C was predominant among poorly differentiated LUAD (p < 0.001) and in LUAD > 1cm (p < 0.05). Further, high expression of CDC25C was associated with reduced disease-free survival (p = 0.03, median follow-up of 39 months) and with a trend for reduced overall survival (p = 0.08). Therefore, high expression of CDC25C protein in LUAD is associated with aggressive histological features and with poor outcomes. Larger studies are required to further validate CDC25C as a prognostic marker in LUAD. Full article
(This article belongs to the Special Issue Editorial Board Members’ Collection Series: "Cancer Biology and Therapeutics")
►▼ Show Figures

Figure 1

Review

Jump to: Research

38 pages, 1805 KiB  
Review
Autoimmunity and Carcinogenesis: Their Relationship under the Umbrella of Autophagy
by Györgyi Műzes and Ferenc Sipos
Biomedicines 2023, 11(4), 1130; https://doi.org/10.3390/biomedicines11041130 - 8 Apr 2023
Cited by 4 | Viewed by 3270
Abstract
The immune system and autophagy share a functional relationship. Both innate and adaptive immune responses involve autophagy and, depending on the disease’s origin and pathophysiology, it may have a detrimental or positive role on autoimmune disorders. As a “double-edged sword” in tumors, autophagy [...] Read more.
The immune system and autophagy share a functional relationship. Both innate and adaptive immune responses involve autophagy and, depending on the disease’s origin and pathophysiology, it may have a detrimental or positive role on autoimmune disorders. As a “double-edged sword” in tumors, autophagy can either facilitate or impede tumor growth. The autophagy regulatory network that influences tumor progression and treatment resistance is dependent on cell and tissue types and tumor stages. The connection between autoimmunity and carcinogenesis has not been sufficiently explored in past studies. As a crucial mechanism between the two phenomena, autophagy may play a substantial role, though the specifics remain unclear. Several autophagy modifiers have demonstrated beneficial effects in models of autoimmune disease, emphasizing their therapeutic potential as treatments for autoimmune disorders. The function of autophagy in the tumor microenvironment and immune cells is the subject of intensive study. The objective of this review is to investigate the role of autophagy in the simultaneous genesis of autoimmunity and malignancy, shedding light on both sides of the issue. We believe our work will assist in the organization of current understanding in the field and promote additional research on this urgent and crucial topic. Full article
(This article belongs to the Special Issue Editorial Board Members’ Collection Series: "Cancer Biology and Therapeutics")
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop